|
Biological Activity:
Selective and orally active inhibitor of phosphodiesterase-4 (PDE4); a potential agent for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD); a second generation PDE4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo.
References: online
TJ Torphy et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulmonary Pharmacol. Ther. 1999, 12(2), 131-135.
H Ochiai et al. Highly potent PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem. Lett. 2004, 14(1), 207-210.
SB Christensen et al. 1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma. J. Med. Chem. 1998, 41(6), 821.
DE Griswold etal. SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo.
J. Pharmacol. Exp. Ther. 1998, 287(2), 705-711. [online]
Chemical Name: 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
| 
